Who this injection is actually for

ChondroFiller is designed for a specific type of hip problem: a focal area of damaged cartilage on the acetabulum in a joint that is otherwise relatively healthy. Before considering the science or the procedure itself, it is worth being clear about who fits that description — and who does not.

Positive criteria

The treatment targets focal Grade III–IV acetabular cartilage defects, typically up to 6 cm² in area, in younger, active adults. The most common reason those defects develop is femoroacetabular impingement (FAI), a condition in which subtle bony abnormalities of the hip joint cause repeated mechanical damage to the cartilage lining the socket. Suitable candidates generally have:

• a discrete, symptomatic lesion confirmed on MRI
• stable, structurally sound cartilage in the surrounding joint
• no significant generalised degeneration of the hip

The exclusion that matters most

The evidence on this boundary is unambiguous. In a prospective cohort study published by Mazek in 2021 (PMC8460160), 26 patients with FAI-related acetabular defects were treated with ChondroFiller during hip arthroscopy and followed for three to five years. Among the 21 patients available at final follow-up, 17 achieved good or excellent results — but patients who entered treatment with Tönnis grade 2–3 osteoarthritis fared poorly. That finding is not a nuance; it is a clear clinical boundary. ChondroFiller is not appropriate for advanced or diffuse hip arthritis, and presenting it as such would be misleading.

Patients whose X-rays or MRI show widespread joint space narrowing, subchondral changes across the hip, or diffuse cartilage loss are likely to need a different conversation — one about hip preservation strategies or, where degeneration is end-stage, joint replacement. A specialist assessment is needed to distinguish a focal defect from generalised wear, which is why MRI confirmation of the lesion's extent and the condition of surrounding cartilage is a practical prerequisite before any treatment decision.

How the collagen scaffold regenerates cartilage

Unlike a corticosteroid injection, which reduces inflammation temporarily, or a hyaluronic acid injection, which supplements joint fluid, ChondroFiller provides a physical framework the body uses to rebuild the damaged surface. The distinction matters because it changes what the treatment is actually asking the hip joint to do.

ChondroFiller is a CE-marked Class III medical device — a murine Type I collagen scaffold delivered in liquid form. Once placed inside the defect, it self-gels within 3–5 minutes, conforming to the contour of the lesion and anchoring the matrix in place without sutures or fixation hardware. No donor cells are introduced at any point. Instead, the scaffold acts as a chemotactic signal, recruiting the patient's own progenitor cells from the surrounding tissue — a process known as matrix-induced chondrogenesis. Those cells migrate into the collagen framework, mature into chondrocytes, and begin laying down new cartilage matrix as the scaffold is gradually resorbed.

The tissue that forms is described as hyaline-like cartilage, which is structurally more durable than the fibrocartilage scar that microfracture typically produces. Microfracture punctures the subchondral bone to trigger a blood-clot repair response; the resulting fibrocartilage is weaker and prone to breakdown at two to three years. A scaffold-based approach aims to avoid that trade-off by guiding differentiation towards the correct tissue type from the outset.

Healing is not immediate. MRI MOCART scores — a validated measure of cartilage repair quality — progress from approximately 65 at four weeks to around 82 at twelve months, reflecting a months-long biological maturation process rather than an instant fill of the defect.

What happens during the ultrasound-guided hip injection

On the day of treatment, patients attend an outpatient clinic appointment — no operating theatre, no general anaesthetic, and no overnight stay. The whole appointment typically takes 15–30 minutes from start to finish.

Before the needle is introduced, a clinician uses a real-time ultrasound probe to map the anatomy of the hip. This step is not optional. The hip is a deep ball-and-socket joint, and the natural approach to the joint capsule runs close to the femoral artery and femoral nerve. Ultrasound guidance gives the clinician continuous, live imaging so the needle can be directed precisely to the front of the hip joint capsule — known as the anterior recess — while keeping clear of those nearby structures. Think of it as navigating by sight rather than estimation.

Once the needle is correctly positioned, the liquid collagen is delivered through a dual-chamber syringe. The two components mix at the moment of injection, and the resulting gel sets within minutes inside the defect. The scaffold fills the lesion and anchors in place without any fixation hardware, as described in the previous section.

Intravenous antibiotic cover is provided as standard throughout the procedure. The treatment package typically includes the initial consultation, the ultrasound guidance, the ChondroFiller device itself, the injection, and a six-week follow-up review.

Most patients are able to leave the clinic on the same day, moving carefully under partial weight-bearing guidance from the outset.

What the clinical evidence shows

The most rigorous hip-specific data come from Mazek et al. (2021), a prospective cohort of 26 adults with FAI-associated acetabular lesions greater than 2 cm² treated with ChondroFiller. At three-to-five-year follow-up, 17 of 21 evaluable patients (81%) had good or excellent results on MRI-confirmed cartilage healing — a meaningful proportion for a single-stage treatment in a population with sizeable focal defects.

Supporting clinical data report a mean Harris Hip Score gain of approximately +33 points and a pain reduction of around 6 points following treatment. MRI MOCART scores — tracking cartilage fill, surface congruity, and integration with native tissue — range from 70 to 87 at twelve months, consistent with the progressive maturation described in the previous section. The worldwide safety record adds a further reassurance signal: more than 19,000 cases have been performed, with a complaint rate of approximately 0.06% in manufacturer clinical evaluation report data.

Two limitations are worth noting. First, the Mazek cohort used arthroscopic delivery during hip surgery; independent peer-reviewed RCT data for the ultrasound-guided injection route specifically are limited. The scaffold's regenerative mechanism is unchanged between delivery routes, but patients and referring clinicians should be aware that the strongest published dataset reflects a surgical rather than injection pathway. Second, no large randomised controlled trial has directly compared ChondroFiller against established cartilage repair techniques in the hip — a gap that remains open in the published literature.

UK access, cost, and how to arrange treatment

ChondroFiller is not currently commissioned by the NHS. Like most advanced cartilage regeneration treatments, it sits outside standard NHS funding, meaning patients access it as a self-funded private treatment. For context, NHS hip cartilage repair — where it is available — centres on autologous chondrocyte implantation (ACI) and bone-marrow derived cell techniques at a small number of specialist commissioned centres, including University Hospital Southampton. ChondroFiller is not among those commissioned options, so patients seeking it will always be self-funding.

In the UK, London Cartilage Clinic (Professor Paul Y.F. Lee, 66 Harley Street) was the first provider to offer ChondroFiller as an ultrasound-guided injection. Hip injection pricing starts from approximately £2,800–£3,000, covering the full treatment package including consultation, imaging guidance, the device, antibiotic cover, and follow-up review. Private medical insurance does not typically cover the treatment.

For patients in Lincolnshire and the wider non-London catchment, the same pathway is accessible through Lincolnshire Hip, part of the MSK Doctors group. Local assessment appointments are available in Sleaford and Grantham. Lincolnshire Hip accepts patients without a GP referral — a referral letter is helpful but not a requirement to book a hip assessment.

Recovery and what to expect in the first year

The first six weeks after the injection are the scaffold's critical establishment phase. Partial weight-bearing during this period is standard — not because the procedure is particularly traumatic, but because the collagen matrix needs mechanical calm while the body's progenitor cells migrate in and begin building new tissue. Loading the joint too heavily before integration is established risks disrupting that process.

From weeks six to twelve, activity is gradually reintroduced under physiotherapy guidance. Most patients notice incremental comfort improvements during this phase, though repair tissue is still maturing and high-impact activity remains off the agenda.

By months three to six, the tissue continues to consolidate. MRI follow-up at this stage tracks the ongoing maturation already described in the outcomes section — the key message for patients is that recovery follows a curve, not a single event. Results build steadily toward the twelve-month mark.

Return to sport or high-impact activity is typically realistic at around 12 months. The biology drives the timeline; expecting meaningful functional recovery in weeks risks overloading cartilage that has not yet fully matured.

Where FAI is the underlying cause of the defect, addressing the bony impingement — conservatively or surgically — remains important for long-term durability. A repaired cartilage surface exposed to continuing mechanical conflict is more vulnerable to re-injury.

ChondroFiller does not damage the subchondral bone plate, which matters if further treatment is ever needed. Should outcomes at twelve months prove insufficient, surgical cartilage restoration options — including MACI or OATS — remain on the table. The injection pathway does not foreclose more intensive repair.